HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $28 to $29.
Read original at benzingaStocks · News reference
Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 5.13 percent. This is unchanged from the same period last year. The company
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:18 PM
- Checked
- Aug 6, 2026, 8:18 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31
JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $28 to $31.
Read original at benzingaCitizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $21 to $26.
Read original at benzingaBarclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30
Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $27 to $30.
Read original at benzinga